Remedy Pharmaceuticals, Inc., located in New York City, is a late-stage specialty pharma focused on therapies capable of transforming treatment in the management of life-threatening brain edema-related conditions − where there are inadequate or no approved existing therapies. CNS-related edema (swelling) is a large unmet medical need that carries significant mortality, morbidity and societal burdens. Solve the problem of edema and you have taken the biggest step forward in the history of treating these patients. How large is this opportunity? For instance, there are 110,000 LHIs in the U.S. each year. CNS-related edema is present in multiple critical care indications, i.e., LHI, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, cardiac arrest, spinal cord injury, etc., as well as in chronic conditions such as brain tumors (primary and metastases). For more information, go to:http://www.remedypharmaceuticals.com
